Management PDF Print E-mail

Our Management Team or Executive Committee is presently responsible for the daily operations of the Scleroderma Care Foundation, realizing its vision, and similarly ensuring its growth and future success.

Adelwyn Holder, Scleroderma Care Foundation Founder and PresidentAdelwyn Holder, Co-Founder & President
Adelwyn Holder currently holds a BA (Hons.) in Business Management from the Anglia Ruskin University and is presently pursuing his post graduate degree, an MBA in Project Management from the Henley Business School. His start with the Scleroderma Care Foundation began as its Co-founder and President in 2008.

This was several years after his own mother and other Co-founder, Susan Le Gendre was diagnosed with Scleroderma in 2004 and having recognized that there were other persons living with Scleroderma in Trinidad & Tobago lacking the necessary support needed to effectively cope with the disease.


Susan Le Gendre, Scleroderma Care Foundation Founder and Vice PresidentSusan Le Gendre, Co-Founder & Vice President
Susan Le Gendre is currently a retired Teacher having been employed for twenty three years with the Ministry of Education. Susan has also worked alongside teaching colleagues on Social and Cultural, Sports and Music Festival Committees. She retired from her Career in Teaching in 2003 after major surgery to the spine.

In 2004 she was diagnosed with Diffuse Systemic Scleroderma. This diagnoses completely undermined life-long plans as she gradually experienced loss of independent functioning, needing assistance for some seemingly simple tasks. God’s love and her family became her source of inspiration and heightened her desire to fight for her life. Susan was instrumental in Co-founding the Scleroderma Care Foundation with Adelwyn.


 
More articles :

» ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy

ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.The patent comes nearly two years after it was developed by University of Tennessee Health...

» The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

Marta Baleva and Krasimir NikolovReceived 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in Scleroderma is...

» A System Out of Breath: How Hypoxia Possibly Contributes to the Pathogenesis of Systemic Sclerosis

T. W. van Hal, L. van Bon, and T. R. D. J. RadstakeReceived 20 May 2011; Revised 18 August 2011; Accepted 7 September 2011Systemic sclerosis (SSc) is typified by vascular alterations and immunological disturbances and fibrosis of the skin and...

» Low-Dose Naltrexone for Pruritus in Systemic Sclerosis

Tracy Frech, Kirsten Novak, Monica P. Revelo, Maureen Murtaugh, Boaz Markewitz, Nathan Hatton, Mary Beth Scholand, Edward Frech, David Markewitz, and Allen D. SawitzkeReceived 31 May 2011; Accepted 14 July 2011Systemic sclerosis (SSc; scleroderma)...

» Systemic Sclerosis Sine Scleroderma

HADI POORMOGHIM, MARY LUCAS, NOREEN FERTIG, and THOMAS A. MEDSGER, JR.ARTHRITIS & RHEUMATISM Vol. 43, No. 2, February 2000, pp 444–451 © 2000, American College of RheumatologyObjectiveTo describe the demographic, clinical, and laboratory...

» A Scleroderma Fact Sheet

Below, is a very useful fact sheet on Scleroderma. Making for much easier reading and reference, this fact sheet highlights what Scleroderma is, how is it diagnosed, who gets it, complications which may arise, and how it can be treated. Feel free to...